Neutralization of SARS-CoV-2 Omicron and Delta Variants in Relation to Vaccine-Induced Antibody Levels in Kidney Transplant Recipients and Healthy Controls
Authors:
- Ditte S. TornbyDTDitte S. Tornby
- the COVAC-TX Study GroupTGthe COVAC-TX Study Group
- Thomas E. AndersenTAThomas E. Andersen
Open Access
- 26 October 2022
- journal article
- letter
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (5) , e0131422
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster VaccinationEmerging Infectious Diseases, 2022
- Virological characteristics of the SARS-CoV-2 Omicron BA.2 spikeCell, 2022
- Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) VariantNew England Journal of Medicine, 2022
- The SARS-CoV-2–neutralizing capacity of kidney transplant recipients 4 weeks after receiving a second dose of the BNT162b2 vaccineKidney International, 2021
- Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapyKidney International, 2021